Soru

Passage A
For decades, researchers studying the placebo effect—the remarkable phenomenon where patients experience genuine clinical improvements after receiving completely inert treatments—have primarily relied on psychological frameworks to explain its mechanisms. According to the dominant psychological model, placebo responses are driven by two interrelated cognitive factors: conscious expectancy and classical conditioning. Expectancy theory posits that a patient's conscious belief in a treatment's efficacy directly influences their subjective experience of symptoms. If a patient is explicitly told that an inert sugar pill is a powerful analgesic, the anticipation of relief reduces the cognitive distress and anxiety associated with pain, thereby diminishing the perceived intensity of the pain itself. Classical conditioning complements this conscious expectation by suggesting that patients unconsciously associate the ritualistic elements of medical treatment—such as white coats, clinical environments, or the physical act of swallowing a pill—with healing, based on their past experiences with actual medications. In this view, the placebo effect is fundamentally a psychological mechanism, an intriguing product of the mind's ability to shape bodily experience through belief and learned mental associations. Therefore, any comprehensive analysis of alternative or placebo-based treatments must evaluate how effectively they harness these underlying cognitive and behavioral dynamics.

Passage B
The traditional view of the placebo effect as a predominantly psychological phenomenon—a subjective trick of the mind where patients simply convince themselves that they are feeling better—has been profoundly challenged by recent advances in neuroimaging and biochemistry. While psychological factors such as expectation undoubtedly play a role in initially triggering the response, the actual mechanism of action is distinctly and observably neurobiological. Functional magnetic resonance imaging (fMRI) studies have conclusively demonstrated that administering a placebo analgesic actively stimulates the brain's descending pain modulatory system, triggering the localized release of endogenous opioids, commonly known as endorphins. This neurochemical cascade is physiologically identical to the response produced by active pharmacological painkillers like morphine. Furthermore, clinical trials have shown that administering an opioid receptor antagonist such as naloxone completely blocks placebo-induced analgesia. This proves that the pain relief is not merely a subjective shift in the patient's attitude or a reduction in anxiety, but a quantifiable, receptor-mediated biochemical event. By demonstrating that placebos initiate specific, observable neurochemical changes in brain chemistry, researchers have established that the placebo effect is a hardwired physiological response. This biological validation shifts the focus of placebo research from the clinic's psychological environment to the laboratory's molecular mapping.

Which one of the following best expresses the joint primary purpose of the two passages?